AngioDynamics Reports Improved Q2 FY26 Results, Reduces Net Loss, and Announces CEO Retirement
ANGO sits 31% above its 52-week low of $8.27.
Summary
AngioDynamics reported strong Q2 FY26 revenue growth and a reduced net loss, driven by its Med Tech segment, alongside the announcement of its CEO's planned retirement in late 2026.
Key Events · Earnings and Guidance · ANGO
-
Strong Revenue Growth
Net sales increased by 9.0% to $79.4 million for the three months ended November 30, 2025, and by 10.6% to $155.1 million for the six months, compared to the prior year periods. This growth was primarily driven by the Med Tech segment, which saw a 13.0% increase in Q2.
-
Reduced Net Loss
The company significantly reduced its net loss, reporting a loss of $6.4 million ($0.15 diluted loss per share) for Q2 FY26, an improvement from a $10.7 million loss ($0.26 diluted loss per share) in the same period last year.
-
Improved Gross Margin
Total company gross margin increased by 160 basis points to 56.4% in Q2 FY26, primarily due to higher sales volume, favorable product mix, and benefits from transitioning product lines to third-party manufacturers.
-
CEO Retirement Announced
James C. Clemmer, President and CEO, notified the Board of his intention to retire by November 30, 2026, or upon the appointment of a successor. A search committee has been formed to identify the next CEO.
Analysis · ANGO · Industrial Applications And Services
AngioDynamics' latest 10-Q filing indicates a positive trend in financial performance, with significant revenue growth and a reduced net loss compared to the prior year. The Med Tech segment, particularly Auryon and thrombus management products, is a key growth driver. While the company continues to operate at a net loss, the improvement in profitability metrics and cash flow from operations suggests a strengthening financial position. The announcement of the CEO's planned retirement in late 2026 introduces future leadership uncertainty, but the established search committee indicates a structured transition process. Investors should monitor the ongoing restructuring efforts and the CEO search for potential impacts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANGO was trading at $10.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $446.6M. The 52-week trading range was $8.27 to $13.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.